Dr. Homa Timlin, MD

Dr. Timlin practices at Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland.

Dr. Timlin's NPI, 1235460866, was assigned on January 21, 2010. Dr. Timlin holds Maryland license D78311.

Dr. Timlin's primary practice is Johns Hopkins Hospital Nelson/Harvey Building, at 600 N Wolfe St, Baltimore, MD 21287 in Baltimore City. The practice phone is (855) 662-3017.

Dr. Timlin's primary practice is Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland. Dr. Timlin is also affiliated with The Johns Hopkins Hospital. The medical group on file is Johns Hopkins University. Dmand AI also links Dr. Timlin to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Timlin practices, 2 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Timlin's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Timlin is licensed in Maryland.

CMS data shows 442 Medicare services from Dr. Timlin across 3 procedure codes in 2024, for 72 Medicare patients. Medicare paid $33,335 for them. Every service was in an office.

CMS counts 72 Medicare patients who saw Dr. Timlin in 2024. The largest group is under 65, with 36 patients. 74% of them have arthritis, and 69% have high blood pressure. 33% are also on Medicaid. Their average risk score is 1.60, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Timlin's median patient age at 51, with 92% women.

In 2024, Dr. Timlin wrote 355 Medicare Part D claims for 63 patients. 88% of them were for generic drugs. CMS names the drug for 298 of them, across 7 drugs with 11 or more claims each, at $351,978 in total drug cost. In 2023, CMS named 195 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Timlin for performance year 2024, reported as part of a group. CMS lists Dr. Timlin as offering telehealth.

Dmand AI links 35 papers to Dr. Timlin, published from 2014 to 2025. 2018 was the busiest year, with 8. The most frequent topics are Lupus Erythematosus, Systemic, Lupus Nephritis and COVID-19. Dr. Timlin has published most often in Cureus. Dr. Timlin's most frequent co-authors are Rebecca L. Manno, MD, Uzma Jala Haque, MD and Eric Jonathan Dein.

Dmand AI links Dr. Timlin to 3 clinical trials. Conditions studied include Lupus Erythematosus, Systemic and Connective Tissue Diseases. Eli Lilly and Company sponsors the most, 3. Open Payments lists research payments to Dr. Timlin that name 3 trials.

CMS Open Payments shows 13 general payments to Dr. Timlin from 8 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 89% of the total. Amgen Inc. paid the most, $250. It also lists 3 research payments totaling $3,641 from 2019 to 2021, naming 3 clinical trials.